Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20857078 | 0.83 | NOTUM (0.40) | NOTUMKDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL22859643 | 0.82 | NOTUM (0.45) | NOTUMKDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL20868509 | 0.82 | NOTUM (0.45) | NOTUMKDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL28896965 | 0.79 | NOTUM (0.41) | NOTUMKDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL28934829 | 0.79 | NOTUM (0.49) | NOTUMKDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL23059425 | 0.79 | NOTUM (0.43) | NOTUMKDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL22480272 | 0.79 | NOTUM (0.43) | NOTUMKDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL25884465 | 0.78 | NOTUM (0.42) | NOTUMKDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL24036185 | 0.77 | NOTUM (0.48) | NOTUMKDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL20857112 | 0.76 | NOTUM (0.47) | NOTUMKDM4EALDH1A1HPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109677-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12605486-B2 | Afibrotic compounds, devices, and uses thereof | SIGILON THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-12522571-B2 | Compounds, devices, and uses thereof | SIGILON THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250235409-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | SIGILON THERAPEUTICS, INC. | 2025-07-24 | — | — | US | disclosed |
| US-12161760-B2 | Implantable particles and related methods | SIGILON THERAPEUTICS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240279187-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-11945786-B2 | Compounds, devices, and uses thereof | SIGILON THERAPEUTICS, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-20230123802-A1 | COMPOSITIONS, DEVICES, AND METHODS FOR FACTOR VII THERAPY | SIGILON THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20220267794-A1 | COMPOSITIONS, DEVICES, AND METHODS FOR TREATING FABRY DISEASE | SIGILON THERAPEUTICS, INC. | 2022-08-25 | — | — | US | disclosed |
| CN-114222590-A | Compositions, devices and methods for factor VII therapy | 西吉隆医疗股份有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-20200263196-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | SIGILON THERAPEUTICS, INC. | 2020-08-20 | — | — | US | disclosed |
| US-20200263196-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | SIGILON THERAPEUTICS, INC. | 2020-08-20 | — | — | US | disclosed |
| EP-3687580-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | Sigilon Therapeutics, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| US-20200039943-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2020-02-06 | — | — | US | disclosed |
| WO-2019195055-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | SIGILON THERAPEUTICS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019195055-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | SIGILON THERAPEUTICS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019195056-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS | SIGILON THERAPEUTICS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019195056-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS | SIGILON THERAPEUTICS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019067766-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | SIGILON THERAPEUTICS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
| WO-2019067766-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | SIGILON THERAPEUTICS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267794-A1 | COMPOSITIONS, DEVICES, AND METHODS FOR TREATING FABRY DISEASE | GLA, GAA, GBA1 | NOTUM 1548/4885KDM4E 4287/4885ALDH1A1 2310/4885 |
| US-20200039943-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SLC10A1, SLCO1B3, SLC5A1 | NOTUM 1471/4885KDM4E 4548/4885ALDH1A1 651/4885 |
| US-11945786-B2 | Compounds, devices, and uses thereof | SLC10A1, SLCO1B3, SLC5A1 | NOTUM 1471/4885KDM4E 4548/4885ALDH1A1 651/4885 |
| US-12161760-B2 | Implantable particles and related methods | TNNT2, TNNI3, TNNC1 | NOTUM 4207/4885KDM4E 4731/4885ALDH1A1 408/4885 |
| US-20250235409-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | TNNT2, TNNI3, TNNC1 | NOTUM 4207/4885KDM4E 4731/4885ALDH1A1 408/4885 |
| US-20240279187-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SLC10A1, SLCO1B3, SLC5A1 | NOTUM 1471/4885KDM4E 4548/4885ALDH1A1 651/4885 |
| US-20230123802-A1 | COMPOSITIONS, DEVICES, AND METHODS FOR FACTOR VII THERAPY | F7, F13B, F9 | NOTUM 4203/4885KDM4E 4003/4885ALDH1A1 2464/4885 |
| US-20260109677-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | NR3C2, AGTR1, CHRM1 | NOTUM 4136/4885KDM4E 4803/4885ALDH1A1 578/4885 |
| US-12605486-B2 | Afibrotic compounds, devices, and uses thereof | SLC11A2, ARG1, COL2A1 | NOTUM 4817/4885KDM4E 2867/4885ALDH1A1 553/4885 |
| US-20200263196-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | ALDH1A2, MYOC, PDE6C | NOTUM 4609/4885KDM4E 4407/4885ALDH1A1 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.